53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
This ERS 2025 abstract from Hyfe's R&D team validates the wear-detection algorithm built into the Hyfe CoughMonitor smartwatch against participant-reported wear status across 418 person-hours of data in ten participants.
Authored by Hyfe's R&D team, this review synthesizes work presented at the European Respiratory Society Congress 2025 and argues that objective cough monitoring has crossed a practical threshold, moving from experimental technique to deployable clinical endpoint.
This study asked whether the core components of BCST could be embedded in a digital therapeutic and paired with continuous, objective cough monitoring inside the CoughPro app.
Cough is a ubiquitous health indicator whose global physical, psychological, and financial burden is extremeand underappreciated. As a disruptive, discrete, and information-rich symptom that is associated with a myriadof diseases, cough is also the ideal clinical endpoint. And yet, even in the age of mobile health, AI, and BigData, cough continues to be assessed mainly through subjective surveys and brief acoustic recordings withbulky and expensive clinical devices. Half the world population now carries smartphones that, when combinedwith AI-powered software, can be used as clinical tools for quantifying cough endpoints objectively.
Scalable mobile cough monitoring has the potential to transform clinical trials by increasing their success rate, decimatingtheir costs, accelerating products to market, and improving health equity worldwide.
